Genetic Risk Assessment for Adult Children of People With Alzheimer’s Disease: The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study

As genetic risk factors continue to be identified for common, complex adult-onset diseases, it will become increasingly important to understand if, how, and when to translate these discoveries into clinical practice. This article provides an overview of and results to date from the REVEAL study, a multisite randomized clinical trial (n = 162) examining the impact of a genetic risk assessment program, including apolipoprotein E genotype disclosure, for adult children of people with Alzheimer’s disease. The study’s rationale and procedures are described, including the generation of numerical lifetime risk curves for use in the education and counseling protocol. Findings are summarized across numerous study questions, including (1) who seeks genetic risk assessment and why, (2) how apolipoprotein E results affect risk perceptions, (3) the psychological impact of genetic risk assessment, and (4) how risk information affects participants’ subsequent health and insurance behaviors.

[1]  A. Roses.  Genetic testing for Alzheimer disease. Practical and ethical issues. , 1997, Archives of neurology.

[2]  R. Green,et al.  Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial , 2004, Genetics in Medicine.

[3]  S. Nolen-Hoeksema,et al.  Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. , 2000, The Gerontologist.

[4]  R. Green,et al.  Predictive Genetic Testing for Alzheimer's Disease: Impact upon Risk Perception , 2005, Risk analysis : an official publication of the Society for Risk Analysis.

[5]  G A Evans.  The Human Genome Project: applications in the diagnosis and treatment of neurologic disease. , 1998, Archives of neurology.

[6]  R. Green,et al.  Reasons for Seeking Genetic Susceptibility Testing Among First‐Degree Relatives of People With Alzheimer Disease , 2003, Alzheimer disease and associated disorders.

[7]  R. Green,et al.  Risk of dementia among white and African American relatives of patients with Alzheimer disease. , 2002, JAMA.

[8]  D. Galton,et al.  Apolipoprotein E genotyping in Alzheimer's disease. , 1996, Lancet.

[9]  P. Panegyres,et al.  Genetic testing for Alzheimer's disease , 2000, The Medical journal of Australia.

[10]  N. Risch,et al.  Estimation of morbid risk and age at onset with missing information. , 1991, American Journal of Human Genetics.

[11]  T. Raffin,et al.  Genetic testing and Alzheimer disease: Has the time come? , 1998, Nature Medicine.

[12]  D. Blacker,et al.  The genetics of Alzheimer disease: current status and future prospects. , 1998, Archives of neurology.

[13]  D. Cella,et al.  A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. , 2002, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[14]  R. Green,et al.  Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: The REVEAL study , 2004, Genetics in Medicine.

[15]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[16]  J. Growdon,et al.  Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study , 1996, Neurology.

[17]  Robertson Js,et al.  Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. , 2000 .

[18]  R. Green,et al.  Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. , 2005, Health affairs.

[19]  K. Garver,et al.  The Human Genome Project and eugenic concerns. , 1994, American journal of human genetics.

[20]  R. Green,et al.  Genetic susceptibility testing versus family history–based risk assessment: Impact on perceived risk of Alzheimer disease , 2005, Genetics in Medicine.

[21]  J. Growdon,et al.  Interrater agreement for diagnosis of Alzheimer's disease , 1994, Neurology.

[22]  A. Roses,et al.  The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. , 1997, JAMA.

[23]  M. Stewart,et al.  Communication patterns of primary care physicians. , 1997, JAMA.

[24]  N. Risch,et al.  Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. , 1995, JAMA.